GlycoMira Therapeutics Inc.
GlycoMira Therapeutics is a development-stage company with potent and patented inflammation-modulating compounds and experienced management.
GTI has developed agents with potential to treat interstitial cystitis (IC), a chronic and debilitating condition. GM-0111, our lead compound, provides an effective new treatment. Current options to treat IC are limited, so urologists are eager for better options. Support groups for IC patients promote new options through social media, making them important customers. The economic impact of IC is large, so third party payers are key stakeholders.